Concepedia
Statistics
Publications
48
Citations
14.3K
H-Index
24
Active since
1981
Affiliations
Sarah Cannon(Current)
Duke University
Kaiser Permanente
Texas Oncology
Vanderbilt University
Thomas H. Cartwright is an author at Sarah Cannon specializing in oncology, medicine, and colorectal cancer.
Publications per year
1981–2022
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text
Medicine, Oncology, Pharmacology +15
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
Frank A. Scappaticci, Louis Fehrenbacher, Thomas H. Cartwright et al. · Journal of Surgical Oncology · 2005 · 531 citations
Medicine, Oncology, Surgery +15
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
Aimery de Gramont, Eric Van Cutsem, Hans‐Joachim Schmoll et al. · The Lancet Oncology · 2012 · 526 citations
Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients
Hans‐Joachim Schmoll, Thomas H. Cartwright, Josep Tabernero et al. · Journal of Clinical Oncology · 2006 · 298 citations
Medicine, Oncology, Pharmacology +17
Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer
Thomas H. Cartwright · Journal of Clinical Oncology · 2002 · 186 citations
1–5 of 48